KPV 10

KVP (10 mg Vial) Dosage Protocol

KPV (10 mg Vial) Dosage Protocol

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects^[1]^[2]. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation^[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 200–500 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	200 mcg	6 units (0.06 mL)
Week 2	300 mcg	9 units (0.09 mL)
Week 3	400 mcg	12 units (0.12 mL)
Weeks 4–8	500 mcg	15 units (0.15 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain manageable injection volumes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability and more precise measurement^[10].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (KPV, 10 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 6 vials
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Concise summary of the once-weekly regimen.

Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects^[1]^[3].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 200–500 mcg daily with gradual weekly titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Suggested weekly titration approach from clinical trials.

Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated^[4]^[5].
Target: 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
Timing: Any consistent time; rotate injection sites systematically.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light^[6]^[7].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days^[7].
Allow vials to reach room temperature before opening to minimize condensation uptake.
Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed^[6].

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use.
Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy^[8].
Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
Document daily dose, injection site, and any observations to maintain consistency and track tolerability.
If injection‑site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant protocol review.

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects^[1]^[2]. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation^[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release^[2]. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols^[4].

Observations from preclinical and early‑stage research.

Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation^[3].
Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability^[4].
Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation^[5].
Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation^[1].

Complementary strategies for optimal metabolic outcomes.

Anti‑inflammatory diet: Emphasize whole foods, omega‑3 fatty acids, polyphenols, and minimize processed foods and refined sugars.
Stress management: Chronic stress elevates inflammatory markers; incorporate stress‑reduction practices (meditation, yoga, adequate sleep).
Physical activity: Regular moderate exercise supports healthy inflammatory balance; avoid overtraining which can increase inflammation.
Sleep optimization: Prioritize 7–9 hours of quality sleep nightly to support immune regulation and inflammatory homeostasis.
Gut health: Support microbiome diversity through probiotic‑rich foods and adequate fiber intake, particularly relevant for inflammatory bowel conditions.

General subcutaneous guidance from clinical best‑practice resources^[8]^[9].

Clean the vial stopper and injection site with alcohol swabs; allow to dry completely (10–15 seconds).
Pinch a 1–2 inch skinfold; insert the needle at 45–90° angle into subcutaneous tissue^[8].
Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds.
Withdraw the needle smoothly and apply gentle pressure with a clean alcohol swab (do not rub the site).
Rotate sites systematically using a pattern (e.g., alternating between right/left abdomen, right/left thigh) to avoid lipohypertrophy and maintain consistent absorption^[9].
Preferred sites: abdomen (at least 2 inches from navel), anterior/lateral thigh, or outer upper arm (if administering to self, abdomen and thigh are easiest).

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. KPV is a research peptide not approved by regulatory agencies for human therapeutic use. Consult qualified healthcare professionals before beginning any peptide protocol. This information is provided for educational and research reference purposes only.

References

— Pawar K. et al.: KPV as an α‑MSH fragment retains potent anti‑inflammatory activity without melanotropic side effects

— Brzoska T. et al.: α‑MSH and related tripeptides: modulation of colitis, inflammation, and melanocortin receptors

— Dalmasso G. et al.: PepT1‑mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models

— KPV peptide benefits, safety, and administration routes; subcutaneous injection for systemic therapy

— KPV dosage calculator and protocol: 200–400 mcg subcutaneously once daily for inflammation and wound healing

— Long‑term peptide stability best achieved in lyophilized form at <−15 °C; avoid extended storage in solution

— Lyophilized peptides stable for short‑term at 4 °C, long‑term at −20 °C; reconstituted solutions refrigerated up to ~30 days

— Subcutaneous injection technique: site preparation, needle angle (45–90°), and injection site rotation

— Best practices for injection: aseptic technique, site preparation, and administration procedures

— Reconstitution in 3 mL yields 3.33 mg/mL; unit/mL conversions; precision syringe recommendations for low volumes

— Subcutaneous injection route guidance: needle angle, site selection, and no aspiration for subcut injections

— Pharmacologic and physiologic considerations of the subcutaneous route for drug administration

— KPV (10 mg) product page: quality documentation, batch COAs, and research‑grade peptide supplier

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on KVP

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

9 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

12 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

15 units

Once daily

Optional research extension

Research use only.

KPV10 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Red Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

KPV 10

KVP (10 mg Vial) Dosage Protocol

KPV (10 mg Vial) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Clinical Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

9 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

12 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

15 units

Once daily

Optional research extension

Research use only.

Red Tier Catalogue

Explore the full British Dragon research line.